AXQ Capital LP Invests $873,000 in DexCom, Inc. $DXCM

AXQ Capital LP acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 12,977 shares of the medical device company’s stock, valued at approximately $873,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Norges Bank bought a new stake in DexCom during the second quarter worth $453,279,000. Groupama Asset Managment increased its stake in shares of DexCom by 79,043.1% during the 2nd quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock worth $350,601,000 after purchasing an additional 4,011,438 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after purchasing an additional 3,410,858 shares during the period. Marshall Wace LLP lifted its stake in DexCom by 260.7% in the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after purchasing an additional 2,762,504 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in DexCom by 82.1% in the 2nd quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company’s stock valued at $317,137,000 after purchasing an additional 1,638,407 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Weiss Ratings cut shares of DexCom from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group set a $95.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, February 13th. Robert W. Baird set a $87.00 price target on DexCom in a research note on Friday, February 13th. Argus reduced their price target on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, TD Cowen dropped their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.18.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $73.26 on Tuesday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $91.87. The stock has a market capitalization of $28.19 billion, a price-to-earnings ratio of 34.89, a price-to-earnings-growth ratio of 1.42 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company’s 50 day simple moving average is $69.64 and its 200 day simple moving average is $69.24.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue was up 13.1% compared to the same quarter last year. During the same period last year, the firm posted $0.45 earnings per share. As a group, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.